MCCORMICK FRANK

SEC source: 0001470831-26-000627 · wk-form4_1782338726.xml · derivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F6 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000627 · wk-form4_1782338726.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,579

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · balance_after: The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5.

F4 · balance_after: Excludes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.

SEC source: 0001193125-26-276048 · ownership.xml · derivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,675

Underlying: Common Stock · 31,675 shares

Expires 2036-06-15

F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

SEC source: 0001470831-25-000282 · wk-form4_1761943122.xml · nonDerivative · entry 5

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Disclosed balance after: 679,979

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

F6 · price: Represents the weighted average sale price of the shares sold from $69.00 to $69.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-25-000282 · wk-form4_1761943122.xml · nonDerivative · entry 4

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Disclosed balance after: 723,372

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

F5 · price: Represents the weighted average sale price of the shares sold from $68.005 to $68.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-25-000282 · wk-form4_1761943122.xml · nonDerivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Disclosed balance after: 731,970

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

F4 · price: Represents the weighted average sale price of the shares sold from $67.00 to $67.996 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-25-000282 · wk-form4_1761943122.xml · nonDerivative · entry 2

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Disclosed balance after: 735,467

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

F3 · price: Represents the weighted average sale price of the shares sold from $66.00 to $66.9875 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-25-000282 · wk-form4_1761943122.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Disclosed balance after: 766,583

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

F2 · price: Represents the weighted average sale price of the shares sold from $65.00 to $65.999 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-25-000278 · wk-form4_1761772228.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Disclosed balance after: 878,338

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

SEC source: 0001257809-25-000003 · wk-form4_1757369187.xml · derivative · entry 4

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,814

Underlying: Common Stock · 74,000 shares

Expires 2033-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

SEC source: 0001257809-25-000003 · wk-form4_1757369187.xml · nonDerivative · entry 2

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,275

F1 · price: Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001257809-25-000003 · wk-form4_1757369187.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,275

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-25-112016 · ownership.xml · derivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,076

Underlying: Common Stock · 91,076 shares

Expires 2035-08-25

F1 · derivative.exercise_date: A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

SEC source: 0000950170-25-090498 · ownership.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017

Disclosed balance after: 879,979

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

F2 · price: Represents the weighted average sale price of the shares sold from $44.00 to $44.69 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0000950170-25-089669 · ownership.xml · derivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089669 · ownership.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83.275

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-25-068335 · ownership.xml · nonDerivative · entry 2

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,686

SEC source: 0000950170-25-068335 · ownership.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,686

SEC source: 0000950170-24-140874 · ownership.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 464,976

SEC source: 0000950170-25-003541 · ownership.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,686

SEC source: 0000950170-24-077447 · ownership.xml · derivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,014

Underlying: Common Stock · 26,014 shares

Expires 2034-06-20

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.

SEC source: 0001209191-23-059885 · doc4.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 627,689

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person, as Trustee of the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 on June 15, 2023.

F2 · price: Represents the weighted average sale price of the shares sold from $42.00 to $42.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017.

SEC source: 0001209191-23-012392 · doc4.xml · derivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,814

Underlying: Common Stock · 158,814 shares

Expires 2033-02-20

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

SEC source: 0001209191-20-059974 · doc4.xml · derivative · entry 4

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 66,326 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

F2 · ownership.nature: The shares are held by the Francis P. McCormick Revocable Trust dated January 27, 2017, of which the Reporting Person is trustee.

SEC source: 0001209191-20-059974 · doc4.xml · derivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 152,891 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

SEC source: 0001209191-20-059974 · doc4.xml · nonDerivative · entry 2

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 84,260

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

F2 · ownership.nature: The shares are held by the Francis P. McCormick Revocable Trust dated January 27, 2017, of which the Reporting Person is trustee.

SEC source: 0001209191-20-059974 · doc4.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,113

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.

SEC source: 0001209191-20-059522 · doc4.xml · derivative · entry 2

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,520

Underlying: Common Stock · 21,520 shares

Expires 2030-11-17

F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0000899243-20-031267 · doc4.xml · nonDerivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200,468

F4 · price: Represents the weighted average sale price of the shares sold from $43.53 to $43.67 per share.

SEC source: 0000899243-20-031267 · doc4.xml · nonDerivative · entry 2

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,210,537

F3 · price: Represents the weighted average sale price of the shares sold from $42.53 to $43.52 per share.

SEC source: 0000899243-20-031267 · doc4.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,268,836

F1 · price: Represents the weighted average sale price of the shares sold from $41.53 to $42.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 3 and 4.

F2 · balance_after: Corrects ending balance which was previously overstated by 100 shares in the Reporting Person's Form 4 filings on May 21, 2020 and December 31, 2019.

SEC source: 0001209191-20-059522 · doc4.xml · derivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,964

Underlying: Common Stock · 56,964 shares

Expires 2030-09-17

F1 · derivative.exercise_date: The shares subject to the option are fully vested.

SEC source: 0000899243-20-013832 · doc4.xml · derivative · entry 2

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,549

Underlying: Common Stock · 10,549 shares

Expires 2029-09-17

F2 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.

SEC source: 0000899243-20-013832 · doc4.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300,568

F1 · kind: The shares were acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer (each, a "Subsidiary" and collectively, the "Subsidiaries").

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 10

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,261,526

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F10 · price: Represents the weighted average sale price of the shares sold from $36.5101 to $37.25 per share.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 9

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,262,426

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F9 · price: Represents the weighted average sale price of the shares sold from $35.36 to $36.31 per share.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 8

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,278,576

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 7

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,278,676

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F8 · price: Represents the weighted average sale price of the shares sold from $41.87 to $42.84 per share.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 6

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,279,293

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F7 · price: Represents the weighted average sale price of the shares sold from $40.77 to $41.76 per share.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 5

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,280,176

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F6 · price: Represents the weighted average sale price of the shares sold from $39.77 to $40.76 per share.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 4

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,297,034

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F5 · price: Represents the weighted average sale price of the shares sold from $38.77 to $39.765 per share.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,310,739

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F4 · price: Represents the weighted average sale price of the shares sold from $37.72 to $38.71 per share.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 2

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,314,239

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F3 · price: Represents the weighted average sale price of the shares sold from $36.68 to $37.50 per share.

SEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,335,895

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019.

F2 · price: Represents the weighted average sale price of the shares sold from $35.68 to $36.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all sales reported in footnotes 2 through 10.

SEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 12

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 290,476 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F7 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

SEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 11

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 418,016 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F6 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

SEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 10

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 406,723 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

SEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 9

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 66,729 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F4 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

SEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 8

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 132,317 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

SEC source: 0000899243-19-019145 · doc4.xml · derivative · entry 7

MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 47,165 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F2 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.